Group items tagged

As of mid-August 2009, there were six (6) lobbyists per single (1) member of House and Senate (Bloomberg News). That's 6:1, folks. Just for healthcare reform. For financial industry reform, there are 2,400 lobbyists in play. The Chamber of Commerce spent $26.2 million--in the first 2 quarters (6 months) of 2009. Clearly, private industries and their foot soldiers on K Street/Capitol Hill influence/dictate American policymaking. No matter who's 'voted in,' it's the influence machine that rules Washington. Worse, there's a good chance that the Supreme Court will grant corporations (as 'fictive persons') to spend unlimited dollars in funding electoral campaigns. Is there hope that this country will be a democracy one day? Or is it doomed to become increasingly, irrevocably plutocratic?

As of mid-August 2009, there were six (6) lobbyists per single (1) member of House and Senate (Bloomberg News). That's 6:1, folks. Just for healthcare reform. For financial industry reform, there are 2,400 lobbyists in play. The Chamber of Commerce spent $26.2 million--in the first 2 quarters (6 months) of 2009.

Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease.\nSiri--Tirino, et al.; \nAm J Clin Nutrition; 2010 Jan 13. \nPMID: 20071648\ndoi:10.3945/ajcn.2009.27725\n\nConclusions: A meta-analysis of prospective epidemiologic studies showed that there is NO significant evidence that dietary saturated fat is associated with increased risk for CHD or CVD. More data are needed to elucidate whether CVD risks are likely to be influenced by the specific nutrients used to replace saturated fat

medical professionals healthcare hospitals schools labs database search dB doctors healthcare opinion-leaders key opinion leaders social-network-analysis SNA people pharma pharmaceutical marketing decision-makers decisionmakers influence

There is reasonable evidence that the use of imiquimod for small (<2 cm) superficial BCC that occur other than on the face provides outcomes only marginally less satisfactory than surgery. There would be a place for imiquimod in treating patients with frequent multiple primary lesions when access to surgery is difficult or where clinical judgment may be influenced by patient factors as reported in some of the studies, eg, where patients may have contraindications to surgery.  It was noted that if recurrences occurred in this study they mostly occurred during the first 9 months after the end of treatment. The initial response was therefore predictive of long-term outcome so these authors recommend and encourage continued monitoring of skin lesions.

Research shows that many doctors rely more on the pharmaceutical industry's own information about a medication than on checking independent sources for evaluations of the drug.